Cat. No. 2977
Chemical Name: 5-(5,6-Dimethoxy-1H-benzimidazol-1-
Biological ActivitySelective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) (IC50 values are 2.2 and 9.1 nM respectively). Displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2. Inhibits proliferation of most tumor cells in vitro and is selective over normal diploid fibroblasts.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Lansing et al (2007) In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol.Cancer Ther. 6 450. PMID: 17267659.
If you know of a relevant reference for GW 843682X please let us know.
Citations are publications that use Tocris products. Selected citations for GW 843682X include:
Hu et al (2015) The Centriole Cartwheel Protein SAS-6 in Trypanosoma brucei Is Required for Probasal Body Biogenesis and Flagellum Assembly. Cell Cycle 14 898. PMID: 26116214.
O'Connor et al (2015) Requirement for PLK1 kinase activity in the maintenance of a robust spindle assembly checkpoint. Eukaryot Cell 5 42624. PMID: 26685311.
Barton et al (2014) Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1. J Cell Biol 206 877. PMID: 25267294.
Hu et al (2013) Polo-like kinase 1 (PLK1) is involved in toll-like receptor (TLR)-mediated TNF-α production in monocytic THP-1 cells. PLoS One 8 e78832. PMID: 24205328.
Colnaghi and Wheatley (2010) Liaisons between survivin and Plk1 during cell division and cell death. Exp Cell Res 285 22592. PMID: 20427271.
Manchado et al (2010) Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. Cancer Cell 18 641. PMID: 21156286.
Pal et al (2010) Role of a novel coiled-coil domain-containing protein CCDC69 in regulating central spindle assembly. J Biol Chem 9 4117. PMID: 20962590.
Scutt et al (2009) Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. J Biol Chem 284 15880. PMID: 19359241.
View Related Products by Product Action
Keywords: GW 843682X, supplier, Selective, inhibitors, inhibits, PLK1, PLK3, Mitosis, Polo-like, Kinases, GW843682X, GlaxoSmithKline, GSK, Tocris Bioscience, Polo-like Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective Brk inhibitorCVT 313
High affinity PKC activator; also APP modulatorJH 295
Irreversible Nek2 inhibitorOXSI 2
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPK
Win a $1,000 travel grant
Bio-Techne is offering 10 travel grants of $1,000 for ISSCR 2017.